G
Gabriel Lopez-Berestein
Researcher at University of Texas MD Anderson Cancer Center
Publications - 11
Citations - 1614
Gabriel Lopez-Berestein is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Gene silencing & Ovarian cancer. The author has an hindex of 11, co-authored 11 publications receiving 1477 citations.
Papers
More filters
Journal ArticleDOI
Regulation of Tumor Angiogenesis by EZH2
Chunhua Lu,Hee Dong Han,Lingegowda S. Mangala,Rouba Ali-Fehmi,Christopher S. Newton,Laurent Ozbun,Guillermo N. Armaiz-Pena,Wei Hu,Rebecca L. Stone,Adnan R. Munkarah,Murali Ravoori,Mian M.K. Shahzad,Mian M.K. Shahzad,Jeong Won Lee,Jeong Won Lee,Edna M. Mora,Edna M. Mora,Robert R. Langley,Amy R. Carroll,Koji Matsuo,Whitney A. Spannuth,Rosemarie Schmandt,Nicholas B. Jennings,Blake W. Goodman,Robert B. Jaffe,Alpa M. Nick,Hye Sun Kim,Hye Sun Kim,Eylem Güven,Ya Huey Chen,Long Yuan Li,Long Yuan Li,Ming Chuan Hsu,Robert L. Coleman,George A. Calin,Emir Baki Denkbaş,Jae Yun Lim,Ju Seog Lee,Vikas Kundra,Michael J. Birrer,Mien Chie Hung,Mien Chie Hung,Gabriel Lopez-Berestein,Anil K. Sood +43 more
TL;DR: It is shown that increased Zeste homolog 2 (EZH2) expression in either tumor cells or in tumor vasculature is predictive of poor clinical outcome, and the potential for targeting ezh2 as an important therapeutic approach is supported.
Journal ArticleDOI
Sustained small interfering RNA delivery by mesoporous silicon particles
Takemi Tanaka,Lingegowda S. Mangala,Pablo E. Vivas-Mejia,René Nieves-Alicea,Aman P. Mann,Edna M. Mora,Edna M. Mora,Hee Dong Han,Mian M.K. Shahzad,Mian M.K. Shahzad,Xuewu Liu,Xuewu Liu,Rohan Bhavane,Jianhua Gu,Jean R. Fakhoury,Jean R. Fakhoury,Ciro Chiappini,Chunhua Lu,Koji Matsuo,Biana Godin,Rebecca L. Stone,Alpa M. Nick,Gabriel Lopez-Berestein,Anil K. Sood,Mauro Ferrari +24 more
TL;DR: The first in vivo therapeutic validation of a novel, multistage siRNA delivery system for sustained gene silencing with broad applicability to pathologies beyond ovarian neoplasms is provided.
Journal ArticleDOI
Targeted gene silencing using RGD-labeled chitosan nanoparticles.
Hee Dong Han,Lingegowda S. Mangala,Jeong Won Lee,Jeong Won Lee,Mian M.K. Shahzad,Mian M.K. Shahzad,Hye Sun Kim,Hye Sun Kim,Deyu Shen,Eun Ji Nam,Eun Ji Nam,Edna M. Mora,Edna M. Mora,Rebecca L. Stone,Chunhua Lu,Sun Joo Lee,Sun Joo Lee,Ju Won Roh,Ju Won Roh,Alpa M. Nick,Gabriel Lopez-Berestein,Anil K. Sood +21 more
TL;DR: In vivo tumor vascular targeting using RGD-CH-NP by delivering PLXDC1-targeted siRNA into the ανβ3 integrin–positive tumor endothelial cells in the A2780 tumor-bearing mice resulted in significant inhibition of tumor growth compared with controls.
Journal ArticleDOI
Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles.
Mian M.K. Shahzad,Mian M.K. Shahzad,Lingegowda S. Mangala,Hee Dong Han,Chunhua Lu,Justin Bottsford-Miller,Masato Nishimura,Edna M. Mora,Edna M. Mora,Jeong Won Lee,Jeong Won Lee,Rebecca L. Stone,Chad V. Pecot,Duangmani Thanapprapasr,Ju Won Roh,Puja Gaur,Maya Nair,Yun-Yong Park,Nirupama Sabnis,Michael T. Deavers,Ju Seog Lee,Lee M. Ellis,Gabriel Lopez-Berestein,Walter J. McConathy,Laszlo Prokai,Andras G. Lacko,Anil K. Sood +26 more
TL;DR: RHDL nanoparticles facilitate highly efficient systemic delivery of siRNA in vivo, mediated by the SR-B1 and are effective in silencing the expression of two proteins key to cancer growth and metastasis in orthotopic mouse models of ovarian and colorectal cancer.
Journal ArticleDOI
Biological roles of the Delta family notch ligand Dll4 in tumor and endothelial cells in ovarian cancer
Wei Hu,Chunhua Lu,Han Hee Dong,Jie Huang,Deyu Shen,Rebecca L. Stone,Alpa M. Nick,Mian M.K. Shahzad,Edna M. Mora,Nicholas B. Jennings,Sun Joo Lee,Ju Won Roh,Koji Matsuo,Masato Nishimura,Blake W. Goodman,Robert B. Jaffe,Robert R. Langley,Michael T. Deavers,Gabriel Lopez-Berestein,Robert L. Coleman,Anil K. Sood +20 more
TL;DR: It is established that Dll 4 plays a functionally important role in both the tumor and endothelial compartments of ovarian cancer and that targeting Dll4 in combination with anti-VEGF treatment might improve outcomes of ovariancancer treatment.